Aug 3, 2017 by Brian Orelli, PhDMomenta Pharmaceuticals, Inc. Treads Water in the Second QuarterWaiting for an FDA approval is hard work.
Aug 3, 2017 by Brian Orelli, PhDWhy OraSure Technologies, Inc. Jumped Higher TodayA solid second quarter from the diagnostic test maker.
Aug 3, 2017 by Brian Orelli, PhDGenomic Health, Inc.: Still Waiting for ReimbursementEven without some of its cancer tests being reimbursed, the diagnostic test company was able to reduce its net loss, putting it on the way toward profitability.
Aug 2, 2017 by Brian Orelli, PhDIDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the MouthIt was a solid quarter for the animal diagnostic company, but investors are worried that guidance wasn't raised enough.
Jul 31, 2017 by Brian Orelli, PhDSeattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)A solid quarter from the biotech, but further substantial sales growth will only come from more FDA approvals.
Jul 31, 2017 by Brian Orelli, PhDImmunoGen, Inc. Earnings: What Goes Up, Must Come DownThe biotech experiences an earnings pop and drop.
Jul 31, 2017 by Brian Orelli, PhDA Beat From Qiagen NV, but Only Half a RaiseAfter a solid quarter, management raises 2017 revenue guidance but leaves earnings guidance intact.
Jul 28, 2017 by Brian Orelli, PhDWhy Shares of ImmunoGen Inc. Shot Up TodayMomentum traders apparently took over after an event-less earnings report.
Jul 28, 2017 by Brian Orelli, PhDCelgene Corporation Continues to Get It DoneDouble-digit revenue growth and increased efficiency leads to an increase in earnings guidance.
Jul 28, 2017 by Brian Orelli, PhDVertex Pharmaceuticals Incorporated Chugs AlongThe biotech continues to sell more of its cystic fibrosis drugs, using the profits to fund development of more drugs. Rinse and repeat.
Jul 27, 2017 by Brian Orelli, PhDBaxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings GrowthOperational efficiencies continue to drive profits at the medical supply company.
Jul 27, 2017 by Brian Orelli, PhDNatus Medical Inc Looks to Turn Things AroundAnother rough quarter for the medical-device maker, but management sees better days ahead.
Jul 26, 2017 by Brian Orelli, PhDBiogen Inc Wants to Be the "Fastest-Growing Large-Cap Biotech Company"After a solid second quarter, management lays out plans for future growth.
Jul 24, 2017 by Brian Orelli, PhDWhy ImmunoGen, Inc. Jumped Higher TodayInvestors might be breathing a sigh of relief, or maybe it's just day traders doing their thing.
Jul 24, 2017 by Brian Orelli, PhDWhy NeuroDerm Ltd Acquired a Higher Price TodayThe biotech will be sold to Mitsubishi Tanabe Pharma.
Jul 13, 2017 by Brian Orelli, PhDHow Biogen Inc. Makes Most of Its MoneyA concentrated revenue source puts the biotech in need of diversification.
Jul 12, 2017 by Brian Orelli, PhDWhy Ocular Theraputix Inc. Saw Its Stock Price Plummet TodayThe FDA rejected its eye-pain treatment for the second time.
Jul 11, 2017 by Brian Orelli, PhDWhy Amicus Therapeutics Inc. Rocketed Higher TodayThe FDA reversed itself and agreed to accept the biotech's current data as a basis for considering approval of Fabry disease treatment migalastat.
Jul 7, 2017 by Brian Orelli, PhDWhy Ocular Therapeutix Inc. Got Beat Down TodayA negative article by STAT has investors worried about the approvability of the biotech's eye drug.
Jun 27, 2017 by Brian Orelli, PhDWhy OraSure Technologies, Inc. Jumped Higher TodayA deal with the Gates Foundation should boost revenue.
